Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat for cerebral perfusion and oxygen metabolism in sickle cell disease
NL-OMON59816Phase 3Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of mitapivat in sickle cell disease (SCD) and sickle cell anemia (SCA), sponsored by Amsterdam University Medical Center. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on NL-OMON59816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59816.